

#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

### 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party — that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

## Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

**Other:** Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent



Section 1. Identifying Info	rmation		
1. Given Name (First Name) Carlijn	2. Surname (Last Name) van der Aalst		3. Date 29-October-2020
4. Are you the corresponding author?	✓ Yes No		
5. Manuscript Title Implementation of lung cancer scree	ning: what are the main issues	?	
6. Manuscript Identifying Number (if you TLCR-20-985	know it)		
Section 2			
Section 2. The Work Under	<b>Consideration for Publica</b>	tion	
any aspect of the submitted work (includ statistical analysis, etc.)? Are there any relevant conflicts of int	ing but not limited to grants, data erest?  Yes  No nformation below. If you have	monitoring board, stu	ent, commercial, private foundation, etc.) for udy design, manuscript preparation, ty press the "ADD" button to add a row.
Name of Institution/Company	Giant	Financial Other?	Comments
European Commission - Horizon 2020	<b>/</b>		grant for European lung cancer screening implementation trial
Section 3. Relevant financi	al activities outside the su	bmitted work.	
	cribed in the instructions. Use	one line for each en	cial relationships (regardless of amount ntity; add as many lines as you need by a <b>36 months prior to publication</b> .
Are there any relevant conflicts of int	erest? ✓ Yes No		
If yes, please fill out the appropriate i	nformation below.		
Name of Entity	Grant	Financial Other?	Comments
Central European Lung Cancer Conference	<b>V</b>	<b>✓</b>	invited speaker, travel costs were paid



Name of Entity	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments	
NIH/National Cancer Institute	<b>✓</b>				Grant: 1U01CA199284-01 Cancer Intervention and Surveillance Modeling Network (CISNET) Lung working group	
Section 4. Intellectual Property						
Do you have any patents, whether plann	ed, pend	ing or issue		nt to the	work? Yes 🗸 No	
Section 5. Relationships not co			porcojvo to bavo i	influonco	d or that give the appearance of	
potentially influencing, what you wrote i				muence	u, or that give the appearance of	
Yes, the following relationships/cond						
At the time of manuscript acceptance, jo On occasion, journals may ask authors to						ents.
Section 6. Disclosure Stateme	nt					
Based on the above disclosures, this form below.	n will auto	omatically (	generate a disclos	sure state	ment, which will appear in the box	
Dr. van der Aalst reports grants from Eur non-financial support from Central Euro the submitted work; .						ž



### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

### The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check

### Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## **Intellectual Property.**

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

## Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether

earning royalties or not

Royalties: Funds are coming in to you or your institution due to your

patent



Section 1. Identifying Inform		
Identifying Inform	ation	
Given Name (First Name)  Kevin	2. Surname (Last Name) ten Haaf	3. Date 02-November-2020
4. Are you the corresponding author?	Yes ✓ No	Corresponding Author's Name Carlijn van der Aalst
5. Manuscript Title Implementation of lung cancer screenir	ng: what are the main issu	es?
6. Manuscript Identifying Number (if you kn TLCR-20-985	ow it)	
Section 2. The Work Under Co	onsideration for Public	cation
	but not limited to grants, da	a third party (government, commercial, private foundation, etc.) for ita monitoring board, study design, manuscript preparation,
If yes, please fill out the appropriate info Excess rows can be removed by pressing		re more than one entity press the "ADD" button to add a row.
Name of Institution/Company	Grant? Personal No	n-Financial Other? Comments
European Union (Horizon 2020)	<b>V</b>	4-IN THE LUNG RUN: towards INdividually tailored INvitations, screening INtervals, and INtegrated co-morbidity reducing strategies in lung cancer screening
Section 3. Relevant financial	activities outside the	ubmitted work.
of compensation) with entities as descri	bed in the instructions. Use ort relationships that we est?	ether you have financial relationships (regardless of amount se one line for each entity; add as many lines as you need by se present during the 36 months prior to publication.



Name of Entity	Grant?	Personal Fees	Non-Financial Support?	Other?	Comments
University of Zurich, Switzerland	<b>✓</b>				Natural history of lung cancer in Switzerland and cost-effectiveness of low-dose computed tomography (LDCT) screening
International Association for the Study of Lung Cancer			<b>/</b>		Invited speaker at the 19th IASLC World Conference on lung cancer in Toronto. Travel expenses in part paid by the IASLC
International Association for the Study of Lung Cancer			<b>/</b>		Invited speaker at the 20th IASLC World Conference on lung cancer in Barcelona Travel expenses in part paid by the IASLC
Cancer Research UK	<b>✓</b>				SELECT: Selection of Eligible People for Lung Cancer Screening using Electronic Primary Care DaTa: Development of new risk prediction models
Russian Society of Clinical Oncology			<b>V</b>		Invited speaker at the 5th RUSSCO Conference on lung cancer in St. Petersburg. Travel expenses paid by RUSSCO
BIOMEDICAL RESEARCH IN ENDSTAGE AND OBSTRUCTIVE LUNG DISEASE HANNOVER (BREATH)			<b>/</b>	<b>✓</b>	Invited speaker at Tagung Thorakale Tumore. Travel expenses paid by BREATH. Erasmus University Medical Center received speaking fees.
NIH/National Cancer Institute	<b>✓</b>				Grant: 1U01CA199284-01 Cancer Intervention and Surveillance Modeling Network (CISNET) Lung working group
Service A					
Section 4. Intellectual Property Patents & Copyrights					
Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes Vo					



Section 5.	Relationships not covered above
	relationships or activities that readers could perceive to have influenced, or that give the appearance of encing, what you wrote in the submitted work?
Yes, the follo	wing relationships/conditions/circumstances are present (explain below):
✓ No other rela	ationships/conditions/circumstances that present a potential conflict of interest
	anuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. Irnals may ask authors to disclose further information about reported relationships.
Section 6.	Disclosure Statement
Based on the abbelow.	ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box
Zurich, Switzerla support from In from Russian So	orts grants from European Union (Horizon 2020), during the conduct of the study; grants from University of and, non-financial support from International Association for the Study of Lung Cancer, non-financial ternational Association for the Study of Lung Cancer, grants from Cancer Research UK, non-financial support ociety of Clinical Oncology, non-financial support and other from BIOMEDICAL RESEARCH IN ENDSTAGE AND UNG DISEASE HANNOVER (BREATH), grants from NIH/National Cancer Institute, outside the submitted

### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

### 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party — that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# 5. Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

**Other:** Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent



Section 1. Identifying Info	rmation		
1. Given Name (First Name) Harry	2. Surname (Last Name) de Koning		3. Date 09-November-2020
4. Are you the corresponding author?	Yes Vo	Corresponding <i>i</i>	
5. Manuscript Title Implementation of lung cancer scree	ning: what are the main issu	ues?	
6. Manuscript Identifying Number (if you TLCR-20-985	ı know it)		
Section 2. The Work Under	Consideration for Publ	ication	
	ing but not limited to grants, d		ernment, commercial, private foundation, etc.) for rd, study design, manuscript preparation,
If yes, please fill out the appropriate i	nformation below. If you ha	ve more than one	entity press the "ADD" button to add a rov
Excess rows can be removed by press  Name of Institution/Company	Grant? Personal No	on-Financial Support?	er? Comments
uropean Commission - Horizon2020	✓ □		grant for European lung cancer screening implementation trial
Section 3. Relevant financi	al activities outside the	submitted wor	k.
of compensation) with entities as de- clicking the "Add +" box. You should Are there any relevant conflicts of int	scribed in the instructions. Use report relationships that we erest?  Yes  No	Ise one line for ea	nancial relationships (regardless of amount ch entity; add as many lines as you need by <b>g the 36 months prior to publication</b> .
If yes, please fill out the appropriate i	nformation below.		
Name of Entity	Grant	on-Financial Support?	Comments
peakers fee			symposium Univeristy of Zurich/MSD
HS England			reviewer IPSOS Mori Targeted Lung Health Checks NHS England



Name of Entity	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments	
NIH/National Cancer Institute	<b>✓</b>				Grant: 1U01CA199284-01 Cancer Intervention and Surveillance Modeling Network (CISNET) Lung working group	
Section 4. Intellectual Propert	v Pate	ents & Coi	ovriahts			
Do you have any patents, whether plann	•			nt to the	work? Yes V No	
Section 5. Relationships not c	overed	above				
Are there other relationships or activities potentially influencing, what you wrote i				nfluence	d, or that give the appearance of	
Yes, the following relationships/cond						
At the time of manuscript acceptance, jo On occasion, journals may ask authors to						ents.
Section 6. Disclosure Statemen						
Disclosure Stateme						
Based on the above disclosures, this forn below.	n will auto	omatically (	generate a disclos	sure state	ment, which will appear in the box	
Dr. de Koning reports grants from Europ from speakers fee , other from NHS Engl				_		



### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.